Limited-stage small-cell lung cancer
Prepared with OnCo (onco.cc/prep/limited-stage-sclc/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
18 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Stage by PET-CT and brain MRI, Response after chemoradiation, Pulmonary function and radiation dose constraints, Neuroendocrine markers on pathology, Transcription factor subtype), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (limited stage, fit), which of the standard options do you recommend and why?
- 6.Am I a candidate for Platinum + etoposide (EP / CE), Cisplatin, Carboplatin or related drugs, and what side effects should I expect?
- 7.How do the results of CONVERT and ADRIATIC apply to someone like me?
- 8.For my situation (after response: brain), which of the standard options do you recommend and why?
- 9.For my situation (stage i, node-negative, found incidentally), which of the standard options do you recommend and why?
- 10.Am I a candidate for Platinum + etoposide (EP / CE), and what side effects should I expect?
- 11.For my situation (relapse), which of the standard options do you recommend and why?
- 12.Am I a candidate for Tarlatamab, Lurbinectedin, Topotecan or related drugs, and what side effects should I expect?
- 13.How do the results of DeLLphi-304 apply to someone like me?
- 14.Are there clinical trials I could join, for example of Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC), Tarlatamab, MRI surveillance replaces prophylactic cranial irradiation in SCLC, Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)?
- 15.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 16.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 17.I read that “Whether prophylactic cranial irradiation still helps when MRI surveillance is available is being tested in randomised trials”. How does that affect my plan?
- 18.I read that “The best radiotherapy dose and schedule to combine with immunotherapy is unknown”. How does that affect my plan?
The words I may hear
- Limited-stage vs extensive-stage (small-cell lung cancer): Small-cell lung cancer uses a two-way split instead of the usual four stages: limited (confined to one side of the chest and treatable within one radiation field, about a third of patients) or extensive (everything else).
- Prophylactic cranial irradiation (PCI): Giving the brain a preventive dose of radiation (25 Gy in 10 sessions) before any metastasis can be seen, mainly in small-cell lung cancer, which spreads to the brain in over half of patients.
- Lobectomy: Removing one lobe of the lung (the right lung has three, the left two).
- Radiation pneumonitis and lung fibrosis: Inflammation of the lung one to six months after chest radiotherapy, causing cough, breathlessness and fever; usually settles with steroids but can leave permanent scarring.
- Consolidation therapy: Treatment given after a good response to kill the cancer cells that are presumably left but cannot be seen, to make the remission last.
- Histologic transformation: When a lung adenocarcinoma escapes targeted therapy by turning into a different cell type, usually small-cell.
- Chemoradiation (chemoradiotherapy, CRT): Radiotherapy given at the same time as chemotherapy, which sensitises the cancer to radiation.
Tests and results to bring
Biomarker results to ask for: Stage by PET-CT and brain MRI (limited versus extensive is the main decision), Response after chemoradiation (eligibility for durvalumab), Pulmonary function and radiation dose constraints, Neuroendocrine markers on pathology (synaptophysin, chromogranin, INSM1), Transcription factor subtype (ASCL1, NEUROD1, POU2F3; research).
Scans and tests linked to this cancer: MRI, PET/CT.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Limited stage, fit: Four cycles of cisplatin or carboplatin plus etoposide with concurrent thoracic radiotherapy (45 Gy twice daily or 60 to 66 Gy once daily) started by cycle two, then durvalumab for up to two years in patients without progression (ADRIATIC). (Platinum + etoposide (EP / CE), Cisplatin, Carboplatin, Etoposide, IMRT / IGRT (modern external beam), Chemoradiation (chemoradiotherapy, CRT), CONVERT, Durvalumab, ADRIATIC, Consolidation therapy)
- Stage I, node-negative, found incidentally: Lobectomy with node dissection then four cycles of platinum-etoposide; radiotherapy if nodes are positive. (Lobectomy, Platinum + etoposide (EP / CE))
- After response: brain: Prophylactic cranial irradiation (25 Gy in 10 fractions) or MRI surveillance every three months in patients who decline it or are older; hippocampal avoidance where available. (Prophylactic cranial irradiation vs MRI surveillance, Prophylactic cranial irradiation (PCI), MRI, MRI surveillance replaces prophylactic cranial irradiation in SCLC)
- Relapse: As for extensive-stage disease: tarlatamab, lurbinectedin or topotecan, or rechallenge with platinum-etoposide if relapse is late. (Tarlatamab, DeLLphi-304, Lurbinectedin, Topotecan, Platinum + etoposide (EP / CE))
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.